HUMAN GENE THERAPY

metrics 2024

Fostering Collaboration in Gene Therapy Research

Introduction

Human Gene Therapy, an esteemed journal published by Mary Ann Liebert, Inc., is at the forefront of the rapidly evolving fields of genetics, molecular biology, and molecular medicine. With a significant impact in its domain, it is categorized in the Q2 quartile across multiple disciplines, reflecting its commitment to disseminating high-quality, impactful research. Established in 1990, the journal has continuously provided a vital platform for scientists and practitioners to explore groundbreaking developments in gene therapy, genetic engineering, and related technologies. With a focus on peer-reviewed articles that foster advancements in therapeutic applications, Human Gene Therapy serves not only as a comprehensive resource for academia but also as an essential reference for professionals engaged in genetic research and clinical practice. Although currently not open access, the journal remains a crucial source of knowledge, driving innovation and collaboration within the gene therapy community.

Metrics 2024

SCIMAGO Journal Rank1.09
Journal Impact Factor3.90
Journal Impact Factor (5 years)5.80
H-Index159
Journal IF Without Self3.90
Eigen Factor0.01
Normal Eigen Factor1.44
Influence1.91
Immediacy Index1.20
Cited Half Life8.60
Citing Half Life6.50
JCI1.00
Total Documents3565
WOS Total Citations6486
SCIMAGO Total Citations53435
SCIMAGO SELF Citations3249
Scopus Journal Rank1.09
Cites / Document (2 Years)2.95
Cites / Document (3 Years)3.21
Cites / Document (4 Years)3.27

Metrics History

Rank 2024

Scopus

Genetics in Biochemistry, Genetics and Molecular Biology
Rank #117/347
Percentile 66.28
Quartile Q2
Molecular Medicine in Biochemistry, Genetics and Molecular Biology
Rank #78/178
Percentile 56.18
Quartile Q2
Molecular Biology in Biochemistry, Genetics and Molecular Biology
Rank #188/410
Percentile 54.15
Quartile Q2

IF (Web Of Science)

BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Rank 50/174
Percentile 71.60
Quartile Q2
GENETICS & HEREDITY
Rank 44/191
Percentile 77.20
Quartile Q1
MEDICINE, RESEARCH & EXPERIMENTAL
Rank 64/189
Percentile 66.40
Quartile Q2

JCI (Web Of Science)

BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Rank 39/174
Percentile 77.59
Quartile Q1
GENETICS & HEREDITY
Rank 46/191
Percentile 75.92
Quartile Q1
MEDICINE, RESEARCH & EXPERIMENTAL
Rank 47/189
Percentile 75.13
Quartile Q1

Quartile History

Similar Journals

TRENDS IN MOLECULAR MEDICINE

Advancing the Frontiers of Molecular Medicine
Publisher: CELL PRESSISSN: 1471-4914Frequency: 12 issues/year

TRENDS IN MOLECULAR MEDICINE, published by CELL PRESS, is a premier journal that stands at the forefront of the rapidly evolving fields of molecular biology and molecular medicine. With a distinguished Q1 ranking in both categories and an impressive Scopus standing—ranked #12 out of 410 in Molecular Biology and #6 out of 178 in Molecular Medicine—this journal is a vital source of high-impact research and insights for researchers, professionals, and students alike. The journal, which has been published consistently since 2000, promotes the dissemination of groundbreaking discoveries that bridge the gap between molecular biology and therapeutic applications. Furthermore, TRENDS IN MOLECULAR MEDICINE embraces modern accessibility options, engaging a global audience eager to explore pioneering advancements in human health. Set against the backdrop of the United Kingdom, this esteemed publication not only informs but also inspires ongoing research and innovation in molecular sciences, making it an essential resource for those shaping the future of medicine.

CURRENT OPINION IN GENETICS & DEVELOPMENT

Innovating understanding in genetics and development.
Publisher: CURRENT BIOLOGY LTDISSN: 0959-437XFrequency: 6 issues/year

CURRENT OPINION IN GENETICS & DEVELOPMENT is a prestigious journal published by CURRENT BIOLOGY LTD that offers an insightful platform for the latest developments and emerging trends in the fields of genetics and developmental biology. Established in 1991 and set to continue until at least 2024, this journal achieves notable recognition in the academic community with a Q1 classification in both its major categories as of 2023. With a Scopus rank placing it within the top quartile for both genetics and developmental biology, it serves as an essential resource for researchers, professionals, and students seeking to enhance their understanding of genetic mechanisms and developmental processes. While currently not an open-access journal, readers can explore the collection of high-quality articles that contribute to shaping contemporary scientific discourse and fostering innovation within these dynamic fields. For those dedicated to advancing their research and knowledge, CURRENT OPINION IN GENETICS & DEVELOPMENT stands as a vital and influential academic publication.

Molecular Therapy Methods & Clinical Development

Transforming science into impactful therapies.
Publisher: CELL PRESSISSN: Frequency: 1 issue/year

Molecular Therapy Methods & Clinical Development, published by CELL PRESS, is a premier Open Access journal dedicated to advancing the field of gene and cell therapy through innovative methodologies and clinical developments. Since its inception in 2014, the journal has garnered significant attention within the research community, achieving impressive Q1 quartile rankings in Genetics, Molecular Biology, and Molecular Medicine as of 2023. With a commendable Scopus ranking that positions it within the top echelons of its categories, this journal serves as an essential platform for researchers, professionals, and students alike, providing access to cutting-edge research that drives the future of therapeutic approaches. With its commitment to Open Access, readers worldwide can easily access high-quality and impactful content that fosters collaboration and knowledge-sharing in this rapidly evolving domain. The journal’s scope encompasses crucial advancements in therapeutic methodologies, ensuring that it remains at the forefront of scientific discourse and innovation.

Lancet Haematology

Advancing hematology through innovative research.
Publisher: ELSEVIER SCI LTDISSN: 2352-3026Frequency: 12 issues/year

Lancet Haematology, published by Elsevier Science Ltd in the United Kingdom, is a premier peer-reviewed journal dedicated to advancing the field of hematology. With an impressive impact factor and listed in the Q1 category in hematology for 2023, this journal ranks #4 out of 137 in the Scopus database, boasting a 97th percentile indicating its influential role in disseminating high-quality research. Since its establishment in 2014, Lancet Haematology has provided a vital platform for researchers and clinicians to share groundbreaking studies, innovative treatment approaches, and novel therapeutic discoveries relevant to various hematological disorders. The journal does not operate under an open access model, but it offers multiple access options to facilitate engagement with its content. By bridging clinical practice and cutting-edge research, Lancet Haematology aims to foster the advancement of knowledge and improve patient outcomes in hematology, making it an essential read for professionals, researchers, and students alike.

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Connecting academics to the pulse of molecular medicine.
Publisher: SPANDIDOS PUBL LTDISSN: 1107-3756Frequency: 12 issues/year

International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.

FUNCTIONAL & INTEGRATIVE GENOMICS

Innovating Insights into Genetic Integration
Publisher: SPRINGER HEIDELBERGISSN: 1438-793XFrequency: 4 issues/year

FUNCTIONAL & INTEGRATIVE GENOMICS, published by Springer Heidelberg, is a leading journal in the fields of genetics and molecular biology. Established in 2000, it serves as a pivotal platform for advancing our understanding of genomic functionality and integration, making significant contributions to both basic and applied research in genetics. With a robust impact factor and a ranking in the Q3 quartile for Genetics and Q2 for Medicine (Miscellaneous), the journal aims to publish innovative research that explores the relationships between genomic data and biological functions, appealing to a diverse audience of researchers and professionals. Although it operates under a subscription model, the journal's extensive archives remain a valuable resource for academics seeking to stay abreast of the latest findings and methodologies in genomics. As the field evolves, FUNCTIONAL & INTEGRATIVE GENOMICS remains committed to fostering scholarly dialogue and the dissemination of groundbreaking studies that influence future research trajectories.

RUSSIAN JOURNAL OF GENETICS

Illuminating Pathways in Genetic Research
Publisher: PLEIADES PUBLISHING INCISSN: 1022-7954Frequency: 12 issues/year

RUSSIAN JOURNAL OF GENETICS is a significant platform in the field of genetics, published by PLEIADES PUBLISHING INC since its inception in 1996. With an ISSN of 1022-7954 and an E-ISSN of 1608-3369, the journal focuses on a wide array of topics within genetics, providing researchers, professionals, and students with insights into advancements and discoveries in this ever-evolving discipline. While it currently holds a Q4 ranking in the 2023 Genetics category according to Scopus, representing invaluable opportunities for knowledge dissemination, the journal is actively working to enhance its impact in future rankings. Readers will find the journal a repository of diverse genetic research findings, methodologies, and theoretical advancements. Although it is not an open-access journal, it is committed to serving the academic community through rigorous peer-reviewed articles. With a consistent publication trajectory spanning to 2024, the RUSSIAN JOURNAL OF GENETICS remains a crucial resource for those aspiring to stay at the forefront of genetic research and applications.

Molecular and Cellular Pediatrics

Empowering researchers to shape the future of pediatrics.
Publisher: SPRINGERNATUREISSN: Frequency: 1 issue/year

Molecular and Cellular Pediatrics is a leading journal published by SPRINGERNATURE, dedicated to advancing knowledge in the fields of pediatrics, perinatology, and child health through innovative molecular and cellular research. Since its transition to Open Access in 2014, the journal has facilitated widespread dissemination of critical findings, making it accessible to a global audience of researchers, healthcare professionals, and students. The journal's scope encompasses a range of topics that explore the intersection of molecular biology and pediatric medicine, aiming to bridge gaps in our understanding of child health and development. With Scopus rankings placing it at the 48th percentile in pediatrics and a significant focus on cutting-edge research, Molecular and Cellular Pediatrics plays an essential role in shaping future research and clinical practices in the field. Its commitment to academic rigor and accessibility makes it a vital resource for those dedicated to improving pediatric health outcomes.

Neurotherapeutics

Unlocking Innovative Therapies for Neurological Disorders.
Publisher: SPRINGERISSN: 1933-7213Frequency: 4 issues/year

Neurotherapeutics, published by Springer, is a leading Open Access journal dedicated to the field of neurology and pharmacology, specifically focusing on innovative therapeutic approaches for neurological disorders. With an impressive impact factor and recognized as a prestigious outlet in its domain—ranking Q1 in Neurology (Clinical) and Pharmacology—this journal serves as an invaluable resource for researchers, healthcare professionals, and students aiming to stay updated with the latest advancements in neurotherapeutics. Since its inception in 2007 and now transitioning to Open Access from 2024, Neurotherapeutics enhances accessibility to high-quality research, ensuring that critical findings reach a global audience. Its current Scopus rankings further underscore its significance, placing it within the top echelons of pharmacology and clinical neurology. By fostering a robust platform for the dissemination of pioneering research, Neurotherapeutics plays a crucial role in shaping the future of neurological treatment and care.

CANCER GENE THERAPY

Pioneering Research in Cancer Gene Therapy
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.